Clinical-stage biopharma creating neuroplastic medicines: engineered combinations of FDA-approved drugs reformulated into single oral capsules to unlock brain rewiring and recovery. Lead program targets reduction of chronic motor disability after stroke; platform also addresses dementia, Parkinson’s, and TBI using a polypharmacology approach and the FDA 505(b)(2) pathway for faster, lower-risk development.